Core Viewpoint - Scilex Holding Company is actively participating in the 2024 Annual PAINWeek conference to present its non-opioid pain management product, ZTlido, highlighting its significance in addressing unmet needs in pain management [1][2]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [4][6]. - The company’s commercial products include ZTlido (lidocaine topical system) 1.8%, ELYXYB (oral solution for migraine treatment), and Gloperba (liquid oral colchicine for gout) [4][5]. Product Presentations - ZTlido will be featured in several presentations at the PAINWeek conference, including a session on optimizing gabapentinoids for neuropathic pain and analyses on decreased opioid and cost utilization compared to traditional lidocaine patches [2]. Research and Development - Scilex has three product candidates in development: SP-102 (dexamethasone gel for sciatica), SP-103 (next-generation lidocaine topical system), and SP-104 (low-dose naltrexone for fibromyalgia) [5]. - SP-102 has completed a Phase 3 study and received Fast Track status from the FDA, while SP-103 has recently completed a Phase 2 trial [5]. Market Positioning - The company targets high unmet needs in pain management, positioning itself to capitalize on large market opportunities with its non-opioid therapies [4].

FDA Final Approval to Precision Dosing for GLOPERBA® Label. We believe GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. According to data gathered by Evaluate Pharma, the gout treatment market is projected to reach $2.0 billion in the U.S ...

Core Insights - Scilex Holding Company announced that the U.S. Patent and Trademark Office will issue a new patent related to the treatment of acute pain, further strengthening its intellectual property for ELYXYB®, an FDA-approved oral solution for acute migraine treatment, expected in late 2024 [1][2] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, targeting high unmet needs and large market opportunities [4][6] - The company’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, with ELYXYB® being the only FDA-approved ready-to-use oral solution for acute migraine treatment [4][5] Market Potential - The U.S. oral migraine drug market was estimated at $1.8 billion in 2022, while the total acute pain market was approximately $3 billion in 2021 [1][4] - There are about 100 million cases of acute pain in the U.S., indicating a significant market opportunity for non-opioid therapies [1][4] Product Efficacy - ELYXYB® has shown rapid pain relief in clinical studies, with patients experiencing relief in as little as 15 minutes and significant pain relief compared to placebo within 45 minutes in about 50% of patients [2][4] - The product is positioned as a first-line non-opioid therapeutic alternative to opioids and acetaminophen, which are associated with risks such as acute liver failure [1][2] Future Developments - The new patent will enable Scilex to file future applications for acute pain treatments, enhancing its product portfolio and market presence [2][4]

Core Insights - Scilex Holding Company has announced a Master Distributor Agreement with Devart Middle East and CH Trading Group to expand the distribution of ZTlido® into Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa [1][2][3] Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [7] - The company's commercial products include ZTlido®, ELYXYB®, and Gloperba®, targeting high unmet needs in pain management [7][8] Product Details - ZTlido® is a lidocaine topical system approved for neuropathic pain relief associated with post-herpetic neuralgia, designed for improved adhesion and continuous pain relief over a 12-hour period [4] - Over one million patients have been treated with ZTlido® in the U.S. since its launch, making it the number one prescribed non-opioid branded pain medication by pain specialists in 2023 [5] Distribution Strategy - The Master Distributor Agreement allows Devart Middle East to promote, market, sell, and distribute ZTlido® and potentially other Scilex products through a network of business associates in the designated territories [3][2] - This agreement builds on an existing Product Distribution Agreement with CH Trading Group, which is expanding ZTlido® commercialization in the Middle East and North/South Africa [2]

Core Insights - Scilex Holding Company has released its inaugural sustainability report, emphasizing its commitment to environmental stewardship, social responsibility, and governance practices [1][2][3] Environmental Stewardship - The company is dedicated to reducing its environmental footprint, recognizing the global impact of environmental health on everyone [2] Development Excellence - Scilex focuses on developing innovative non-opioid pain management products to address significant unmet medical needs, aiming to improve patient lives [2][3] Social Responsibility - The company emphasizes ethical business practices, respecting employee rights, and fostering an inclusive environment for its workforce and supply chain [2][3] Governance - Scilex promotes transparent corporate governance to ensure accountability and balance the interests of its stakeholders, including patients, suppliers, and employees [2] Strategic Focus - The company's strategy includes advancing patient health, expanding access to non-opioid pain management products, and investing in scientific excellence to expedite the availability of medicines [3]

PALO ALTO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the release of its inaugural sustainability report which highlights sustainability efforts by the company related to its environmental footprint, contributing positively to society, and improving access ...

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its Chief Executive Officer and President, Jaisim Shah, and Executive Chairman, Henry Ji, Ph.D., will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York, at 4:00 p.m. Eastern ...

The ceremony will be held in celebration of Scilex's launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K _______________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2024 _______________________ • ZTlido net sales for the month ended June 30, 2024 were in the range of $7.5 million to $9.0 million, compared to $4.4 million for the same period last year, representing growth in the range of approximately ...

Investors and Media Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Office: (650) 516-4310 ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year. ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year. Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year. Total product net sales for the quarter e ...